에피제네틱스 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 기술별, 용도별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Epigenetics Market Summary

The global epigenetics market size was valued at USD 19.1 billion in 2025 and is projected to grow from USD 21.9 billion in 2026 to USD 63.2 billion by 2033, at a CAGR of 16.4% from 2026 to 2033. North America held the largest share of 38.7% of the global market in 2025. This growth can be attributed to the pivotal role of epigenetics in understanding gene regulation beyond DNA sequencing, aiding disease research, and advancing personalized medicine.

Global Epigenetics Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global epigenetics market report on the basis of product, technology, application, end use, and region:

• Product Outlook (Revenue, USD Billion, 2021 - 2033)
• Reagents
• Kits
  • ChIP sequencing kit
  • Whole Genomic Amplification kit
  • Bisulfite Conversion kit
  • RNA sequencing kit
  • Others
• Instruments
• Enzymes
• Services
• Technology Outlook (Revenue, USD Billion, 2021 - 2033)
• DNA Methylation
• Histone Methylation
• Histone Acetylation
• Large non - coding RNA
• MicroRNA modification
• Chromatin structures
• Application Outlook (Revenue, USD Billion, 2021 - 2033)
• Oncology
  • Solid tumors
  • Liquid tumors
• Non - oncology
  • Inflammatory diseases
  • Metabolic diseases
  • Infectious diseases
  • Cardiovascular diseases
  • Others
• End Use Outlook (Revenue, USD Billion, 2021 - 2033)
• Academic Research
• Clinical Research
• Hospitals & Clinics
• Pharmaceutical & Biotechnology Companies
• Other Users
• Regional Outlook (Revenue, USD Billion, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Product Segment
  • 1.2.2. Technology Segment
  • 1.2.3. Application Segment
  • 1.2.4. End Use Segment
• 1.3. Information Analysis
• 1.4. Market Formulation & Data Visualization
• 1.5. Data Validation & Publishing
• 1.6. Research Assumptions
• 1.7. Information Procurement
  • 1.7.1. Primary Research
• 1.8. Information or Data Analysis
• 1.9. Market Formulation & Validation
• 1.10. Market Model
• 1.11. Global Market: CAGR Calculation
• 1.12. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables & Trends

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing prevalence of cancer
    • 3.2.1.2. Rising Investment in Precision Medicine
    • 3.2.1.3. Expansion of Epigenetics-Based Drug Discovery
    • 3.2.1.4. Technological Advancements in Sequencing and Multi-Omics
    • 3.2.1.5. Increasing Research Funding and Government Support
    • 3.2.1.6. Rising Biopharmaceutical R&D Expenditure
    • 3.2.1.7. Expansion of Liquid Biopsy and Non-Invasive Diagnostics
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Lack of standardization in epigenetics-based diagnostics
    • 3.2.2.2. Lack of skilled professionals
  • 3.2.3. Market Opportunity Analysis
  • 3.2.4. Market Challenge Analysis
• 3.3. Case Study Insights
• 3.4. Industry Analysis Tools
  • 3.4.1. Porter's Analysis
    • 3.4.1.1. Bargaining power of the suppliers
    • 3.4.1.2. Bargaining power of the buyers
    • 3.4.1.3. Threats of substitution
    • 3.4.1.4. Threats from new entrants
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Economic and Social landscape
    • 3.4.2.3. Technological landscape
    • 3.4.2.4. Environmental landscape
    • 3.4.2.5. Legal landscape

Chapter 4. Product Business Analysis

• 4.1. Product Segment Dashboard
• 4.2. Epigenetics Market Product Movement Analysis
• 4.3. Epigenetics Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Billion)
• 4.4. Reagents
  • 4.4.1. Reagents Market, 2021 - 2033 (USD Billion)
• 4.5. Kits
  • 4.5.1. Kits Market, 2021 - 2033 (USD Billion)
  • 4.5.2. ChIP sequencing kit
    • 4.5.2.1. ChIP sequencing kit Market, 2021 - 2033 (USD Billion)
  • 4.5.3. Whole Genomic Amplification kit
    • 4.5.3.1. Whole Genomic Amplification kit Market, 2021 - 2033 (USD Billion)
  • 4.5.4. Bisulfite Conversion kit
    • 4.5.4.1. Bisulfite Conversion kit Market, 2021 - 2033 (USD Billion)
  • 4.5.5. RNA sequencing kit
    • 4.5.5.1. RNA sequencing kit Market, 2021 - 2033 (USD Billion)
  • 4.5.6. Others
    • 4.5.6.1. Others Market, 2021 - 2033 (USD Billion)
• 4.6. Instruments
  • 4.6.1. Instruments Market, 2021 - 2033 (USD Billion)
• 4.7. Enzymes
  • 4.7.1. Enzymes Market, 2021 - 2033 (USD Billion)
• 4.8. Services
  • 4.8.1. Services Market, 2021 - 2033 (USD Billion)

Chapter 5. Technology Business Analysis

• 5.1. Technology Segment Dashboard
• 5.2. Epigenetics Market Technology Movement Analysis
• 5.3. Epigenetics Market Size & Trend Analysis, by Technology, 2021 to 2033 (USD Billion)
• 5.4. DNA Methylation
  • 5.4.1. DNA Methylation Market, 2021 - 2033 (USD Billion)
• 5.5. Histone Methylation
  • 5.5.1. Histone Methylation Market, 2021 - 2033 (USD Billion)
• 5.6. Histone Acetylation
  • 5.6.1. Histone Acetylation Market, 2021 - 2033 (USD Billion)
• 5.7. Large non - coding RNA
  • 5.7.1. Large non - coding RNA Market, 2021 - 2033 (USD Billion)
• 5.8. MicroRNA modification
  • 5.8.1. MicroRNA modification Market, 2021 - 2033 (USD Billion)
• 5.9. Chromatin structures
  • 5.9.1. Chromatin structures Market, 2021 - 2033 (USD Billion)

Chapter 6. Application Business Analysis

• 6.1. Application Segment Dashboard
• 6.2. Epigenetics Market Application Movement Analysis
• 6.3. Epigenetics Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Billion)
• 6.4. Oncology
  • 6.4.1. Oncology Market, 2021 - 2033 (USD Billion)
  • 6.4.2. Solid tumors
    • 6.4.2.1. Solid tumors Market, 2021 - 2033 (USD Billion)
  • 6.4.3. Liquid tumors
    • 6.4.3.1. Liquid tumors Market, 2021 - 2033 (USD Billion)
• 6.5. Non - oncology
  • 6.5.1. Non - oncology Market, 2021 - 2033 (USD Billion)
  • 6.5.2. Inflammatory diseases
    • 6.5.2.1. Inflammatory diseases Market, 2021 - 2033 (USD Billion)
  • 6.5.3. Metabolic diseases
    • 6.5.3.1. Metabolic diseases Market, 2021 - 2033 (USD Billion)
  • 6.5.4. Infectious diseases
    • 6.5.4.1. Infectious diseases Market, 2021 - 2033 (USD Billion)
  • 6.5.5. Cardiovascular diseases
    • 6.5.5.1. Cardiovascular diseases Market, 2021 - 2033 (USD Billion)
  • 6.5.6. Others
    • 6.5.6.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 7. End Use Business Analysis

• 7.1. End Use Segment Dashboard
• 7.2. Epigenetics Market End Use Movement Analysis
• 7.3. Epigenetics Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Billion)
• 7.4. Academic Research
  • 7.4.1. Academic Research Market, 2021 - 2033 (USD Billion)
• 7.5. Clinical Research
  • 7.5.1. Clinical Research Market, 2021 - 2033 (USD Billion)
• 7.6. Hospitals & Clinics
  • 7.6.1. Hospitals & Clinics Market, 2021 - 2033 (USD Billion)
• 7.7. Pharmaceutical & Biotechnology Companies
  • 7.7.1. Pharmaceutical & Biotechnology Companies Market, 2021 - 2033 (USD Billion)
• 7.8. Other Users
  • 7.8.1. Other Users Market, 2021 - 2033 (USD Billion)

Chapter 8. Regional Business Analysis

• 8.1. Epigenetics Market Share by Region, 2025 & 2033
• 8.2. North America
  • 8.2.1. North America Epigenetics Market, 2021 - 2033 (USD Billion)
  • 8.2.2. U.S.
    • 8.2.2.1. Key Country Dynamics
    • 8.2.2.2. Competitive Scenario
    • 8.2.2.3. Regulatory Framework
    • 8.2.2.4. U.S. Epigenetics Market, 2021 - 2033 (USD Billion)
  • 8.2.3. Canada
    • 8.2.3.1. Key Country Dynamics
    • 8.2.3.2. Competitive Scenario
    • 8.2.3.3. Regulatory Framework
    • 8.2.3.4. Canada Epigenetics Market, 2021 - 2033 (USD Billion)
  • 8.2.4. Mexico
    • 8.2.4.1. Key Country Dynamics
    • 8.2.4.2. Competitive Scenario
    • 8.2.4.3. Regulatory Framework
    • 8.2.4.4. Mexico Epigenetics Market, 2021 - 2033 (USD Billion)
• 8.3. Europe
  • 8.3.1. Europe Epigenetics Market, 2021 - 2033 (USD Billion)
  • 8.3.2. UK
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Competitive Scenario
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. UK Epigenetics Market, 2021 - 2033 (USD Billion)
  • 8.3.3. Germany
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Competitive Scenario
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Germany Epigenetics Market, 2021 - 2033 (USD Billion)
  • 8.3.4. France
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Competitive Scenario
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. France Epigenetics Market, 2021 - 2033 (USD Billion)
  • 8.3.5. Italy
    • 8.3.5.1. Key Country Dynamics
    • 8.3.5.2. Competitive Scenario
    • 8.3.5.3. Regulatory Framework
    • 8.3.5.4. Italy Epigenetics Market, 2021 - 2033 (USD Billion)
  • 8.3.6. Spain
    • 8.3.6.1. Key Country Dynamics
    • 8.3.6.2. Competitive Scenario
    • 8.3.6.3. Regulatory Framework
    • 8.3.6.4. Spain Epigenetics Market, 2021 - 2033 (USD Billion)
  • 8.3.7. Denmark
    • 8.3.7.1. Key Country Dynamics
    • 8.3.7.2. Competitive Scenario
    • 8.3.7.3. Regulatory Framework
    • 8.3.7.4. Denmark Epigenetics Market, 2021 - 2033 (USD Billion)
  • 8.3.8. Sweden
    • 8.3.8.1. Key Country Dynamics
    • 8.3.8.2. Competitive Scenario
    • 8.3.8.3. Regulatory Framework
    • 8.3.8.4. Sweden Epigenetics Market, 2021 - 2033 (USD Billion)
  • 8.3.9. Norway
    • 8.3.9.1. Key Country Dynamics
    • 8.3.9.2. Competitive Scenario
    • 8.3.9.3. Regulatory Framework
    • 8.3.9.4. Norway Epigenetics Market, 2021 - 2033 (USD Billion)
• 8.4. Asia Pacific
  • 8.4.1. Asia Pacific Epigenetics Market, 2021 - 2033 (USD Billion)
  • 8.4.2. Japan
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Japan Epigenetics Market, 2021 - 2033 (USD Billion)
  • 8.4.3. China
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. China Epigenetics Market, 2021 - 2033 (USD Billion)
  • 8.4.4. India
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. India Epigenetics Market, 2021 - 2033 (USD Billion)
  • 8.4.5. Australia
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Competitive Scenario
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Australia Epigenetics Market, 2021 - 2033 (USD Billion)
  • 8.4.6. Thailand
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Competitive Scenario
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Thailand Epigenetics Market, 2021 - 2033 (USD Billion)
  • 8.4.7. South Korea
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Competitive Scenario
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. South Korea Epigenetics Market, 2021 - 2033 (USD Billion)
• 8.5. Latin America
  • 8.5.1. Latin America Epigenetics Market, 2021 - 2033 (USD Billion)
  • 8.5.2. Brazil
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Brazil Epigenetics Market, 2021 - 2033 (USD Billion)
  • 8.5.3. Argentina
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Argentina Epigenetics Market, 2021 - 2033 (USD Billion)
• 8.6. MEA
  • 8.6.1. MEA Epigenetics Market, 2021 - 2033 (USD Billion)
  • 8.6.2. South Africa
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. South Africa Epigenetics Market, 2021 - 2033 (USD Billion)
  • 8.6.3. Saudi Arabia
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Saudi Arabia Epigenetics Market, 2021 - 2033 (USD Billion)
  • 8.6.4. UAE
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Competitive Scenario
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. UAE Epigenetics Market, 2021 - 2033 (USD Billion)
  • 8.6.5. Kuwait
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Competitive Scenario
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Kuwait Epigenetics Market, 2021 - 2033 (USD Billion)

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
• 9.2. Strategy Mapping
• 9.3. Company Market Position/Share Analysis, 2025
• 9.4. Company Profiles
  • 9.4.1. Thermo Fisher Scientific Inc.
    • 9.4.1.1. Overview
    • 9.4.1.2. Financial Performance
    • 9.4.1.3. Product Benchmarking
    • 9.4.1.4. Strategic Initiatives
  • 9.4.2. Illumina, Inc.
    • 9.4.2.1. Overview
    • 9.4.2.2. Financial Performance
    • 9.4.2.3. Product Benchmarking
    • 9.4.2.4. Strategic Initiatives
  • 9.4.3. Danaher Corporation (Abcam)
    • 9.4.3.1. Overview
    • 9.4.3.2. Financial Performance
    • 9.4.3.3. Product Benchmarking
    • 9.4.3.4. Strategic Initiatives
  • 9.4.4. Promega Corporation
    • 9.4.4.1. Overview
    • 9.4.4.2. Financial Performance
    • 9.4.4.3. Product Benchmarking
    • 9.4.4.4. Strategic Initiatives
  • 9.4.5. New England Biolabs
    • 9.4.5.1. Overview
    • 9.4.5.2. Financial Performance
    • 9.4.5.3. Product Benchmarking
    • 9.4.5.4. Strategic Initiatives
  • 9.4.6. QIAGEN
    • 9.4.6.1. Overview
    • 9.4.6.2. Financial Performance
    • 9.4.6.3. Product Benchmarking
    • 9.4.6.4. Strategic Initiatives
  • 9.4.7. Merck KGaA (MilliporeSigma)
    • 9.4.7.1. Overview
    • 9.4.7.2. Financial Performance
    • 9.4.7.3. Product Benchmarking
    • 9.4.7.4. Strategic Initiatives
  • 9.4.8. Active Motif
    • 9.4.8.1. Overview
    • 9.4.8.2. Financial Performance
    • 9.4.8.3. Product Benchmarking
    • 9.4.8.4. Strategic Initiatives
  • 9.4.9. EpiCypher
    • 9.4.9.1. Overview
    • 9.4.9.2. Product Benchmarking
    • 9.4.9.3. Financial Performance
    • 9.4.9.4. Strategic Initiatives
  • 9.4.10. Element Biosciences
    • 9.4.10.1. Overview
    • 9.4.10.2. Financial Performance
    • 9.4.10.3. Product Benchmarking
    • 9.4.10.4. Strategic Initiatives